Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 601–700 of 1,001
Holst, J. J. (2002) · BioDrugs · doi:10.2165/00063030-200216030-00002 · Cited by 24
“Indeed, several studies have shown that the incretin effect, as studied by comparing the insulin or C-peptide responses to isoglycaemic oral and intravenous glucose challenges, is abolished or severely reduced in all of the patients investigated.[40,41] Since it is now possible to identify the discrete components of t…”
BackgroundTrzaskalski, N. A., Vulesevic, B., Nguyen, M.-A., Jeraj, N., Fadzeyeva, E., Morrow, N. M., Locatelli, C. A. A., Travis, N., Hanson, A. A., Nunes, J. R. C., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.154314 · Cited by 21
“In patients with T2D, there is a defect in the incretin-mediated potentiation of insulin secretion (7).”
Antidiabetic Drugs in Breast Cancer Patients
Garczorz, W., Kosowska, A., & Francuz, T. (2024) · Cancers · doi:10.3390/cancers16020299 · Cited by 23
“The incretin effect is significantly impaired in people with type 2 diabetes, mainly due to the reduced secretion of GLP-1 [69,70].”
BackgroundThe incretin pathway as a new therapeutic target for obesity
Barber, T. M., Begbie, H., & Lévy, J. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.06.018 · Cited by 31
Marre, M., & Penfornis, A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.004 · Cited by 25
“However, in patients with T2DM, the incretin effect is impaired and incretin hormone activity is reduced [17,18].”
BackgroundFreeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 24
Tzefos, M., Harris, K., & Brackett, A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q379 · Cited by 21
Ohlsson, B., Höglund, P., Roth, B., & Darwiche, G. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.12.004 · Cited by 22
“Incretins account for approximately 70% of postprandial insulin secretion [9, 10].”
Kanda, J., Furukawa, M., Izumo, N., Shimakura, T., Yamamoto, N., Takahashi, H. E., & Wakabayashi, H. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.03073 · Cited by 22
“A previous study demonstrated that the actions of GIP and GLP-1 are reduced in patients with T2DM compared to those in healthy individuals (20,21).”
ResultNovel therapeutics and targets for the treatment of diabetes
Aicher, T. D., Boyd, S. A., McVean, M., & Celeste, A. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.1 · Cited by 22
Drucker, D. J. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706287651 · Cited by 21
“Conversely, people with type 2 diabetes show a reduction in meal-stimulated GLP-1 secretion, although they retain sensitivity to its actions.(38,39) Research has demonstrated that increasing exposure to GLP-1 has beneficial effects for people with type 2 diabetes, including the promotion of glucose-dependent insulin s…”
BackgroundThe Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function
Cordiner, R. L. M., Mari, A., Tura, A., & Pearson, E. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab151 · Cited by 22
“This study has strengths in the use of the goldstandard technique for physiological evaluation of the incretin effect and demonstrates results in line with observations from previous incretin physiology studies in type 2 diabetes (1,35).”
BackgroundMethodResultInfluentialGreen, J. (2010) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s6270 · Cited by 22
Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes
Han, S. J., Kim, H. J., Choi, S., KANG, Y. Y., Lee, K. W., & Kim, D. J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.06.004 · Cited by 20
“[1] Nauck M, Stockmann F, Ebert R, Creutzfeldt W.”
BackgroundCirculating glucagon-like peptide-1 increases in response to short-term overfeeding in men
Wadden, D., Cahill, F., Amini, P., Randell, E. W., Vasdev, S., Yi, Y., Church, J. G., & Sun, G. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-33 · Cited by 23
“For example, both its incretin effect and suppression of glucagon secretion action are disrupted in type-II diabetes [17].”
BackgroundZhang, S., Wang, S., Puhl, M. D., Jiang, X., Hyrc, K. L., Laciny, E., Wallendorf, M., Pappan, K. L., Coyle, J. T., & Wice, B. M. (2014) · Diabetes · doi:10.2337/db14-1188 · Cited by 21
“4E and F) increased only in WT mice after nutrient administration, indicating that as in humans with T2DM (5), the incretin response is severely blunted in DT mice.”
BackgroundWu, T., Zhang, X., Trahair, L. G., Bound, M. J., Little, T. J., Deacon, C. F., Horowitz, M., Jones, K. L., & Rayner, C. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2813 · Cited by 21
Tura, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., Vilsbøll, T., & Mari, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.10.006 · Cited by 24
Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins
Ríos, J.-L., Andújar, I., Schinella, G. R., & Francini, F. (2019) · Planta Medica · doi:10.1055/a-0897-7492 · Cited by 21
Nauck, M. A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154031 · Cited by 22
Self-citationProtein Glycosylation in Diabetes
Štambuk, T., & Gornik, O. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-70115-4_14 · Cited by 26
GIP: An Inconsequential Incretin or Not?
Pratley, R. E. (2010) · Diabetes Care · doi:10.2337/dc10-0704 · Cited by 19
“A total of 29 older obese men and women with either NGT (n 16) or newly-diagnosed type 2 diabetes (n 13) participated in a 3-month weight loss and exercise intervention.”
BackgroundInfluentialA Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa081 · Cited by 21
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus
Tanaka, S., Kanazawa, I., Notsu, M., & Sugimoto, T. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.027 · Cited by 25
Diabetes medication pharmacology
Stubbs, D. J., Levy, N., & Dhatariya, K. (2016) · BJA Education · doi:10.1093/bjaed/mkw075 · Cited by 23
“People with T2DM have very low concentrations of GLP-1 compared with those without the condition.(18) Endogenous GLP-1 has a circulating half-life of 2 min because it is broken down by an endogenous circulating enzyme called DPP-4.”
BackgroundIoakim, K. J., Sydney, G. I., & Paschou, S. Α. (2019) · HORMONES · doi:10.1007/s42000-019-00147-z · Cited by 20
Reilly, A. M., Yan, S., Huang, M., Abhyankar, S. D., Conley, J. M., Bone, R. N., Stull, N. D., Horan, D. J., Roh, H. C., Robling, A. G., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101431 · Cited by 19
“Blunted incretin effects have been reported in diabetic patients, as measured by the percent increase in insulin secretion of oral versus intravenous glucose injection (39).”
BackgroundEnteroendocrine System and Gut Barrier in Metabolic Disorders
Osinski, C., Moret, D., Clément, K., Serradas, P., & Ribeiro, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073732 · Cited by 22
“The incretin effect, which enhances glucose-dependent insulin secretion in the postprandial state, is impaired in subjects with T2D, explained by combined effects of reduced GLP-1 secretion and impaired GIP action [77,78].”
BackgroundHeruc, G. A., Horowitz, M., Deacon, C. F., Feinle‐Bisset, C., Rayner, C. K., Luscombe‐Marsh, N. D., & Little, T. J. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00370.2014 · Cited by 21
Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients
Škrha, J., Hilgertová, J., Jarolimkova, M., Kunešová, M., & Hill, M. (2010) · Physiological Research · doi:10.33549/physiolres.931893 · Cited by 22
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors
Kim, K., & Jang, H.-J. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/171742 · Cited by 21
“Indeed, lowered plasma active GLP-1 levels observed in T2DM patients support the GLP1 receptor agonism as an appropriate therapeutic strategy [9].”
BackgroundMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00297-5 · Cited by 21
Self-citation[Ser2]- and [Ser(P)2]Incretin Analogs
Hinke, S. A., Manhart, S., Kühn‐Wache, K., Nian, C., Demuth, H., Pederson, R. A., & McIntosh, C. H. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311304200 · Cited by 21
RAMPs regulate signalling bias and internalisation of the GIPRPreprint
Harris, M., Mackie, D. I., Pawlak, J. B., Carvalho, S., Truong, T. T., Safitri, D., Yeung, H. Y., Routledge, S. J., Harper, M. T., Al‐Zaid, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.08.436756 · Cited by 23
“After its release, it is rapidly broken down by dipeptidylpeptidase IV (DPPIV) 16 to GIP (3-42), a weak partial agonist.”
BackgroundMethodInfluentialFadini, G. P., Albiero, M., & Avogaro, A. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.08.004 · Cited by 19
Watkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 23
Miller, L. J., Sexton, P. M., Dong, M., & Harikumar, K. G. (2014) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2014.4 · Cited by 24
Add-on therapies to metformin for type 2 diabetes
Shomali, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.542150 · Cited by 19
“In healthy individuals, the plasma insulin response to intravenous glucose averages between 30 and 70% less than the insulin response to oral glucose ingestion [38]; this finding pointed to the contribution of the incretin hormones GLP-1 and GIP to meal-based insulin stimulation [39,49].”
BackgroundFrandsen, C. S., & Madsbad, S. (2014) · Diabetic Medicine · doi:10.1111/dme.12561 · Cited by 18
Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
“The first of the two main therapeutic strategies for utilising he incretin effect in T2DM therefore involves the inhibition of de diffuser ce document. etabo D v a d s u [ r a t a [ l [ w o a i a m 1 d s h w g [ c a a 4 p a r r a c a n I w b w w a c b r t o o b g [ t d 3 c d y 4 m s e i t 3 s f [ c v f t a i i l t w a…”
BackgroundInfluentialUnderstanding GLP-1 Analogs and Enhancing Patient Success
Kruger, D. F., Bode, B. W., & Spollett, G. R. (2010) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721710374370 · Cited by 19
“In patients with type 2 diabetes, the difference in insulin secretion following intravenous and oral glucose is smaller compared with individuals who do not have diabetes (Figure 3, right panel).(14) An inadequate postprandial rise in GLP-1 and decreased β-cell responsiveness to GIP appear to underlie this blunted eff…”
BackgroundLaferrère, B. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.01.010 · Cited by 18
“Fasting bile acids levels have been shown to be elevated after GBP in a cross sectional study36 and 3 months after malabsorptive bariatric procedure.65 Bile acids after bypass are related to peak GLP136 and to fasting GIP levels.65 We recently reported a strong association between bile acids and GLP-1 up to 2 years af…”
InfluentialKampmann, K., Ueberberg, S., Menge, B. A., Breuer, T. G. K., Uhl, W. H., Tannapfel, A., & Meier, J. J. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.025 · Cited by 21
“[10] Nauck M, Stöckmann F, Ebert R, Creutzfeldt W.”
BackgroundFrom organophosphate poisoning to diabetes mellitus: The incretin effect
Rathish, D., Agampodi, S. B., Jayasumana, M. A. C. S., & Siribaddana, S. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.04.002 · Cited by 23
“[5] Nauck M, Stöckmann F, Ebert R, Creutzfeldt W.”
BackgroundInfluentialBallav, C., & Gough, S. C. L. (2013) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7314 · Cited by 24
What role will 'gliptins' play in glycemic control?
BLOOMGARDEN, Z., & DREXLER, A. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.4.305 · Cited by 18
Moonschi, F. H., Hughes, C. B., Mussman, G. M., Fowlkes, J. L., Richards, C. I., & Popescu, I. R. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1086-7 · Cited by 18
Astiarraga, B., Chueire, V. B., de Souza, A. L., Moreira, R. P., Alegre, S. M., Natali, A., Tura, A., Mari, A., Ferrannini, E., & Muscelli, E. (2018) · Diabetologia · doi:10.1007/s00125-018-4633-z · Cited by 21
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16–18].”
BackgroundDomínguez-Vías, G., Segarra, A. B., Ramírez‐Sánchez, M., & Prieto, I. (2020) · Nutrients · doi:10.3390/nu12030636 · Cited by 17
“GLP-1 is an incretin hormone with antidiabetic action that is capable of stimulating insulin secretion [18,19], increasing beta cell neogenesis [20], inhibiting beta cell apoptosis [20], inhibiting glucagon secretion [21], delaying gastric emptying, and inducing satiety [20,21].”
Guccio, N., Alcaino, C., Miedzybrodzka, E. L., Santos-Hernández, M., Smith, C. A., Davison, A., Bakar, R. B., Kay, R. G., Reimann, F., & Gribble, F. M. (2024) · Diabetologia · doi:10.1007/s00125-024-06293-3 · Cited by 19
“Plasma GIP concentrations in humans rise rapidly following oral glucose ingestion and act as an early signal to pancreatic islets that glucose is being absorbed [6].”
InfluentialEffects of Proximal Gut Bypass on Glucose Tolerance and Insulin Sensitivity in Humans
Breitman, I., Isbell, J. M., Saliba, J., Jabbour, K., Flynn, C. R., Marks–Shulman, P. A., Laferrère, B., Abumrad, N. N., & Tamboli, R. A. (2013) · Diabetes Care · doi:10.2337/dc12-1722 · Cited by 17
“The incretin effect on insulin secretion (2) was increased ;20% with jejunal compared with gastric delivery (54 vs.”
BackgroundZhang, L., Song, X., Zhou, L., Liang, G., Xu, H., Wang, F., Huang, F., & Jiang, G. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0194-9 · Cited by 18
“These results indicated that 3DG-treated rats displayed obviously pancreatic islet cell dysfunction that is one of the typical characteristic of T2DM.”
BackgroundInfluentialASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management
ASGE EndoVators Task Force, Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., & Mergener, K. (2017) · Surgical Endoscopy · doi:10.1007/s00464-017-5934-x · Cited by 17
Jia, S., Wang, Z., Han, R., Zhang, Z., Li, Y., Qin, X., Zhao, M., Xiang, R., & Yang, J. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01542-4 · Cited by 18
“Although moderate-quality evidences in other analysis showed that the SGLT-2is plus Met was superior to DPP-4is plus Met [97], different drugs plus Met may produce varying degrees of synergistic effect because of their complementary mechanisms.”
ResultGlucolipotoxicity and GLP-1 secretion
Hong, J.-H., Kim, D., & Lee, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001905 · Cited by 17
Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 20
Foghsgaard, S., Vedtofte, L., Andreasen, C. H., Andersen, E. S., Bahne, E., Bagger, J. I., Svare, J., Holst, J. J., Clausen, T. D., Mathiesen, E. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4265-8 · Cited by 19
Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm
Green, J., & Feinglos, M. N. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01438.x · Cited by 20
Gastric Inhibitory Polypeptide (GIP) Response in Diabetes Using a Highly Specific Antiserum
Alam, M. J., Kerr, J. I., Cormican, K., & Buchanan, K. D. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01835.x · Cited by 19
Diabetes Technology: Monitoring, Analytics, and Optimal Control
Kovatchev, B. P. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034389 · Cited by 17
“In particular, the incretin response is de fi cient (Nauck et al. 1986b), and this fi nding triggered the introduction of new classes of medications known as GLP-1 receptor agonists (incretin mimetics), and DPP-4 inhibitors (incretin enhancers) (Drucker and Nauck 2006).”
BackgroundKalli, S. B., & Velmurugan, V. (2022) · Pharmacia · doi:10.3897/pharmacia.69.e95096 · Cited by 18
Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice
Murthy, T. A., Chapman, M. J., Jones, K. L., Horowitz, M., & Marathe, C. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.447 · Cited by 17
Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment
Halabi, A., Maatouk, H., Siegler, K. E., Faisst, N., & Hinrichsen, H. M. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.89 · Cited by 16
“In diabetic patients there is a significant reduction inmeal-stimulated insulin secretion, which leads to postprandial hyperglycemia.(1,2) The dipeptidyl peptidase IV (DPP-IV) inhibitors target the incretin hormone system and thereby promote insulin secretion by increasing the levels of active glucagon-like-peptide-1…”
BackgroundMadsbad, S. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.11.003 · Cited by 19
“Polypeptide (GIP), which is responsible for one-half to two-half of the insulin secreted during a meal is severely impaired in people with type 2 diabetes [2–4].”
BackgroundInoué, T., Hagiyama, M., Yoneshige, A., Kato, T., Enoki, E., Maenishi, O., Chikugo, T., Kimura, M., Satou, T., & Ito, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100988 · Cited by 16
Cardiovascular protective properties of incretin-based therapies in type 2 diabetes
Şimşek, S., & de Galan, B. E. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283590b8f · Cited by 17
“Patients with T2DM have a reduced incretin response compared with healthy individuals, which contributes significantly to impaired glucose homeostasis [14].”
BackgroundAdapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes
Salvatore, T., Carbonara, O., Cozzolino, D., Torella, R., & Sasso, F. C. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802076 · Cited by 17
Pujadas, G., Nigris, V. D., Sala, L. L., Testa, R., Genovese, S., & Ceriello, A. (2015) · Endocrine · doi:10.1007/s12020-015-0799-z · Cited by 17
Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances
Gallwitz, B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000217 · Cited by 18
“The incretin effect is diminished in type 2 diabetes (T2D), mainly because of a loss of the insulinotropic function of GIP [3].”
BackgroundUnderstanding Bone Disease in Patients with Diabetic Kidney Disease: a Narrative Review
Hauge, S. C., Frost, M., & Hansen, D. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00630-2 · Cited by 19
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1985465 · Cited by 19
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
Yu, C. H. J., Migicovsky, Z., Song, J. I., & Rupasinghe, H. P. V. (2022) · Plants People Planet · doi:10.1002/ppp3.10315 · Cited by 17
The pathophysiologic role of incretins.
Freeman, J. S. (2007) · PubMed · Cited by 17
Carlson, O. D., David, J. D., Schrieder, J. M., Muller, D. C., Jang, H.-J., Kim, B.-J., & Egan, J. M. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.009 · Cited by 19
“By accounting for up to 60% of the insulin secretory response after an oral glucose load, they play important roles in promoting nutrient assimilation, regulating energy absorption, and maintaining glucose homeostasis [45].”
BackgroundThe incretin system and cardiometabolic disease
Szmitko, P. E., Leiter, L. A., & Verma, S. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70010-6 · Cited by 18
“Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.”
BackgroundInfluentialIslet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes
Pratley, R. E. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)70004-x · Cited by 16
Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes
Goswami, G., Shinkazh, N., & Davis, N. J. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3020595 · Cited by 18
Zhang, X., Liu, Y., Xiong, D., & Xie, C. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12352 · Cited by 17
Pancreatic beta-cell function and islet-cell proliferation: Effect of hyperinsulinaemia
Koiter, T. R., Wijkstra, S., van der Schaaf-Verdonk, G. C. J., Moes, H., & Schuiling, G. A. (1995) · Physiology & Behavior · doi:10.1016/0031-9384(94)00290-8 · Cited by 16
Novel insights into the effects of diabetes on gastric motility
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1129898 · Cited by 16
“The ‘incretin effect’ is markedly reduced in T2DM [74] and although the etiology remains conten-”
BackgroundHtike, Z. Z., Yates, T. E., Brady, E. M., Webb, D. R., Gray, L. J., Swarbrick, D. J., McCann, G. P., Khunti, K., & Davies, M. J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0421-6 · Cited by 19
“GLP-1 is secreted from the small intestine in response to oral glucose ingestion and is a potent stimulator of insulin secretion [22].”
BackgroundKoopman, A. D. M., Rutters, F., Rauh, S. P., Nijpels, G., Holst, J. J., Beulens, J. W. J., Alssema, M., & Dekker, J. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191114 · Cited by 17
Role of Surgery in Management of Type 2 Diabetes Mellitus
Herron, D. M., & Tong, W. W. Y. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20114 · Cited by 20
Khajavi, N., Finan, B., Kluth, O., Müller, T. D., Mergler, S., Schulz, A., Kleinau, G., Scheerer, P., Schürmann, A., Gudermann, T. W., et al. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.07.006 · Cited by 18
Tripolt, N. J., Hofer, S. J., Pferschy, P. N., Aziz, F., Durand, S., Aprahamian, F., Nirmalathasan, N., Waltenstorfer, M., Eisenberg, T., Obermayer, A. M., et al. (2023) · Nutrients · doi:10.3390/nu15030511 · Cited by 17
“While the oral glucose tolerance test leads to a blood glucose induced and incretin induced stimulation of the insulin secretion from the pancreas, the IVGTT stimulates insulin secretion by the rapid increase in blood glucose only [27].”
BackgroundŁuniewski, M., Matyjaszek‐Matuszek, B., & Lenart-Lipińska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134431 · Cited by 16
“In addition, insulin resistance in obese individuals results from improperly low secretion and increased degradation of incretin hormones, such as GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory polypeptide) [40,41].”
BackgroundPoly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Thus, any defect in the incretin axis leads to impaired insulin secretion, as seen in T2D [57].”
Li, J., Xie, J., Han, Y., Zhang, W., Wang, Y., & Jiang, Z. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0286 · Cited by 19
Incretin therapy and its effect on body weight in patients with diabetes
Lind, M. (2012) · Primary care diabetes · doi:10.1016/j.pcd.2012.04.006 · Cited by 15
“In healthy individuals, incretin hormones are responsible for up to 70% of postprandial insulin secretion, but in T2D the incretin effect is significantly reduced [1].”
BackgroundInfluentialO’Brien, P., Han, G., Ganpathy, P., Pitre, S., Zhang, Y., Ryan, J., Sim, P. Y., Harding, S., Gray, R., Preedy, V. R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010137 · Cited by 15
“In diabetes, GLP1 secretion is only mildly attenuated [70].”
BackgroundKong, X., Feng, L., Yan, D., Li, B., Yang, Y., & Ma, X. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16339 · Cited by 19
“14,31,32 It is also necessary to note that, although chronic hyperglycaemia decreases GLP-1R expression, it does not affect expression of PKA and Epac2 in β - cells.”
BackgroundGiuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.43 · Cited by 19
“Clinicians should be aware of these findings and consider the use of these drugs when appropriate to improve health outcomes and reduce the prevalence of obesity-related disability, which is frequently observed in people with T2D. q”
BackgroundInfluentialImpact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 16
“In T2D, the incretin effect is deficient [32, 33] and reduced levels of GLP-1 have been reported individually in some participants as well as in groups with T2D, but this does not seem to be an universal characteristic of all patients with T2D [33].”
Using albumin to improve the therapeutic properties of diabetes treatments
Åhrén, B., & Burke, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01482.x · Cited by 18
Sakai, T., Kusakabe, T., Ebihara, K., Aotani, D., Yamamoto‐Kataoka, S., Zhao, M., Gumbilai, V., Ebihara, C., Aizawa‐Abe, M., Yamamoto, Y., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00272.2014 · Cited by 16
“However, in patients with type 2 diabetes, the insulinotropic effect of GLP-1 is substantially reduced (15, 29).”
Background
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.